Freed from the exhausting arithmetic of pill schedules
No Brasil, onde mais de 53 mil pessoas convivem com o Parkinson avançado, a Anvisa aprovou um dispositivo vestível que entrega medicação contínua sob a pele, sem cirurgia e sem os rígidos horários de comprimidos que há décadas definem o cotidiano desses pacientes. O Vyalev, da AbbVie, combina dois compostos que restauram os níveis de dopamina ao longo de 24 horas, oferecendo ao corpo aquilo que a doença progressivamente retira: o controle do próprio movimento. É um avanço que não cura, mas que devolve horas — horas de presença, de trabalho, de vida compartilhada.
- Para pacientes em estágio avançado do Parkinson, cada hora sem tremores ou rigidez é uma conquista disputada contra o relógio dos comprimidos — e esse relógio muitas vezes falha.
- Os ensaios clínicos revelaram uma diferença concreta: quase três horas a mais por dia de função motora plena com o Vyalev, contra menos de uma hora com a medicação oral convencional.
- O dispositivo elimina tubos externos, adere diretamente à pele com adesivo hipoalergênico e é controlado por smartphone, permitindo que pacientes se exercitem, tomem banho e durmam sem interrupções terapêuticas.
- A aprovação pela Anvisa abre o acesso formal ao tratamento no Brasil, mas a velocidade com que chegará aos 53 mil pacientes — e se chegará àqueles sem plano de saúde privado — ainda é uma questão em aberto.
- Para os 61% dos pacientes com comorbidades, que enfrentam opções ainda mais restritas, o Vyalev representa uma alternativa que antes simplesmente não existia no arsenal terapêutico brasileiro.
A Anvisa aprovou na segunda-feira o Vyalev, um dispositivo vestível da AbbVie que administra medicação contínua para pacientes com Parkinson avançado — sem cirurgia, sem tubos externos e sem a disciplina exaustiva dos horários de comprimidos. O aparelho combina foslevodopa e foscarbidopa, entregues sob a pele ao longo de 24 horas, para restaurar os níveis de dopamina e recuperar o controle motor que a doença progressivamente destrói. Uma vez instalado por um profissional de saúde, o dispositivo opera em segundo plano, controlado por smartphone ou controle remoto.
A diferença clínica é expressiva: em estudos de 12 semanas, pacientes com o Vyalev ganharam 2,72 horas adicionais por dia de função motora plena, contra 0,97 horas com a levodopa oral convencional. Essas horas a mais significam movimento sem tremor, capacidade de trabalhar, de estar presente com a família — uma medida de liberdade que a doença havia subtraído.
O Brasil conta com cerca de 53.674 pessoas vivendo com Parkinson, e 61% delas têm outras condições de saúde que complicam o tratamento. Para esse grupo — em estágios avançados, sem resposta às terapias convencionais — o Vyalev oferece algo inédito no país. O que ainda resta saber é se o custo do dispositivo permitirá que ele alcance a maioria dos que precisam, ou se ficará restrito a quem tem plano privado ou recursos próprios.
Brazil's health regulator gave the green light on Monday to a new treatment for advanced Parkinson's disease—a wearable pump that delivers medication continuously throughout the day without requiring surgery or the rigid pill schedules that have long defined the disease's management.
The device, called Vyalev and manufactured by AbbVie, represents a shift in how doctors can treat patients whose symptoms have become severe and who have not responded well to conventional therapies. It works by delivering two active compounds—foslevodopa and foscarbidopa—directly under the skin over a 24-hour cycle. The foslevodopa raises dopamine levels in the body to restore motor control, while the foscarbidopa amplifies that therapeutic effect. Parkinson's itself is a degenerative neurological condition in which the brain gradually loses neurons that produce dopamine, leading to progressive loss of movement control. There is no cure, only management of symptoms.
What makes Vyalev different from older treatments is both its delivery method and its setup. Unlike deep brain stimulation, which requires invasive surgery, the wearable pump can be fitted and configured in a doctor's office. The device itself is small and tube-free, adhering directly to the skin with a hypoallergenic adhesive. A tiny needle is inserted beneath the skin during application, and the pump is controlled remotely via smartphone or a small handheld device. Because there are no external tubes or wires, patients can exercise, shower, and sleep normally—freedoms that the old oral medication regimen, with its strict dosing schedule, did not allow.
The clinical evidence supporting the approval is substantial. In 12-week trials, patients using Vyalev experienced 2.72 additional hours per day of optimal motor function—what doctors call "On" time—compared to just 0.97 hours gained by those taking standard oral levodopa and carbidopa pills. That difference translates directly into more hours each day when a person can move without tremor or rigidity, can work, can engage with family, can live.
Brazil has approximately 53,674 people living with Parkinson's disease, according to national health data. Sixty-one percent of them have other medical conditions alongside the disease, which complicates their treatment and often limits their options. For this population—people in advanced stages of the disease who have exhausted conventional approaches—Vyalev offers something that did not exist before: continuous, non-surgical medication delivery that does not demand the constant vigilance of a pill schedule. The device is programmed and placed by a healthcare professional, but once it is working, it operates in the background, freeing patients from the exhausting arithmetic of timing doses and managing breakthrough symptoms between pills.
The approval marks a moment when a treatment that was once only theoretical has become available to Brazilian patients. What remains to be seen is how quickly it reaches those who need it most, and whether the cost of the device will be accessible to the broader population or remain limited to those with private insurance or substantial means.
Notable Quotes
The device can be fitted and configured in a doctor's office without invasive surgery— Anvisa approval documentation
The Hearth Conversation Another angle on the story
Why does a wearable pump matter so much for Parkinson's patients specifically? Couldn't they just take more pills?
Because Parkinson's doesn't cooperate with a pill schedule. As the disease advances, the brain's ability to store dopamine breaks down. You take a pill, it works for two or three hours, then it wears off sharply. You're trapped in cycles of "on" and "off." A continuous pump smooths that out—your dopamine levels stay steady all day.
And that 2.72 extra hours of good function—is that really life-changing?
It is. That's nearly three more hours a day when your hands don't shake, when you can walk without freezing, when you can feed yourself or hold a conversation without struggling. Multiply that by 365 days. It's the difference between being housebound and being able to work, to see friends, to have a life.
Why hasn't something like this existed before?
It has existed for insulin and pain medication. But Parkinson's treatment has been stuck in the oral pill era for decades. The science of wearable infusion is proven; it just took time and investment for a company to develop the right drug combination and get regulatory approval.
What's the catch?
Cost, almost certainly. And whether the Brazilian health system will cover it. A wearable pump with continuous medication delivery is expensive. Right now it's approved, but access is another question entirely.